Severity Assessment in CDKL5 Deficiency Disorder.

Area of Science:

• Genetics and Neurology
• Rare Disease Research
• Clinical Assessment Tool Development

Background:

• Cyclin-dependent kinase-like 5 (CDKL5) mutations cause CDKL5 deficiency disorder (CDD), a genetic condition characterized by severe epilepsy and developmental impairments.
• CDD is a frequent genetic cause of epilepsy in early life, affecting cognitive, motor, visual, and autonomic functions.
• A standardized severity assessment is currently lacking, hindering clinical course monitoring, natural history definition, and clinical trial readiness.

Purpose of the Study:

• To develop a comprehensive severity assessment tool for CDKL5 deficiency disorder.
• To establish a standardized method for evaluating disease severity and monitoring patient progression.
• To facilitate clinical trial readiness and natural history studies for CDD.

Main Methods:

• Development involved clinical and research expertise from international consortia (International Foundation for CDKL5 Research Centers of Excellence, NIH Rett and Rett-Related Disorders Natural History Study).
• A modified Delphi process with multiple iterations was employed, engaging clinicians, researchers, industry, patient groups, and parents.
• The assessment was refined through feedback and piloting with families at international meetings.

Main Results:

• A 51-item severity assessment was finalized, covering epilepsy, motor, cognitive, behavioral, visual, speech, and autonomic domains.
• The assessment includes parental ratings on therapy effectiveness and overall child and family functioning.
• The tool provides a comprehensive description of CDD manifestations.

Conclusions:

• A severity assessment for CDKL5 deficiency disorder was rapidly developed through multi-stakeholder consensus.
• Ongoing validation is necessary to support its use in future clinical trials.
• The consensus methodology used may serve as a model for developing assessments in other rare disorders.